2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009


Cannabis Science Enters Select, New High-Dosage Product Line of CBD, Sativa, and Indica Capsules Into the Industry-Famous Emerald Cup Event This Weekend in Santa Rosa, CA

Cannabis Science Enters Select, New High-Dosage Product Line of CBD, Sativa, and Indica Capsules Into the Industry-Famous Emerald Cup Event This Weekend in Santa Rosa, CA

COLORADO SPRINGS, CO--(Marketwired - Dec 10, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, will debut, represent, and compete at The Emerald Cup competitions for the prestigious awards. Cannabis Science has entered 3 products into 2 categories. The 2015 Emerald Cup is taking place in Santa Rosa, California on December 12th and 13th and will feature more than 150 different cannabis-related vendors for attendees to get samples and purchase products.

The Company is excited to debut three of its select newest high-dose products at The Emerald Cup Event, which has been running for 12 years in Northern California. The event features music, speakers, sampling, vendor booths, and a variety of different contests. Cannabis Science will have dedicated staff whose primary goal is to interact with the public, hand out product brochures, network with dispensaries, and other industry professionals, take pictures, and improve the company's brand equity.

"We are ecstatic to see the results of The Emerald Cup cannabis competition. This is one of the biggest and most highly regarded outdoor, organic cannabis contests in the world. We think our products could be top contenders," said Director, President & CEO Raymond C. Dabney. "Our team is second to none; even if we don't win, we will reach new customers in ways we have not yet been able to, and that is ultimately one of the primary goals at this event. Our guys will be roaming the floors interacting with the general public, giving product samples and forging new relationships. We are very proud of their accomplishments!"

THE 2015 EMERALD CUP AWARDS consist of a total of 9 product categories, which will be awarded on stage at The Emerald Cup Awards ceremony on Sunday, December 13th. Cannabis Science has entered 3 products into 2 categories:

3) Edibles Category

Product entered: "CBIS 100mg, Indica"

Product entered: "CBIS 25mg, Sativa"

*Awards given for the top 10 entries

8) CBD Edibles Category

Product entered: "CBIS 50mg, 1:1 CBD to THC Capsules"

*Awards given for the top 3 entries

** The contest winners will be posted on The Emerald Cup website on Sunday, December 13th, after the awards ceremony. Results will be posted here: http://theemeraldcup.com/winners/

Relevant Links:
http://cannabisscience.com/
https://www.instagram.com/CBISCORP/
https://twitter.com/CannabisScienc1
https://www.facebook.com/Cannabis-Science-Inc-1496646807286333/?fref=ts
https://plus.google.com/105654137913057550481
http://theemeraldcup.com/

About The Emerald Cup

The Emerald Cup is a cannabis-centered festival and competition promoting the growth and use of natural, ethically, sun-grown cannabis. It will feature a multitude of vendors, speakers, artists, dispensaries, and collectives and will be held in Santa Rosa, California on December 12th and 13th, 2015.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.